Oncology Institute (TOI) Stock Price, News & Analysis

Company Overview

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Key Stats

• Today's Range: $4.87 to $5.15
• 50-Day Range: $4.77 to $6.28
• 52-Week Range: $2.32 to $6.67
• Volume: 1.26 million shs
• Average Volume: 1.92 million shs
• Market Capitalization: $512.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 67% of companies evaluated by MarketBeat, and ranked 277th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncology Institute has a consensus price target of $8.50, representing about 63.9% upside from its current price of $5.19.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncology Institute are expected to grow in the coming year, from ($0.18) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -14.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncology Institute is -14.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.57% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 4.83.

Change versus previous month

Short interest in Oncology Institute has recently decreased by 1.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $203,804.00 in company stock, which represents 0.0398% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have bought 161.54% more of their company's stock than they have sold. Specifically, they have bought $329,970.00 in company stock and sold $126,166.00 in company stock.

Percentage Held by Insiders

4.40% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

36.86% of the stock of Oncology Institute is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/01/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: theoncologyinstitute.com
• Phone: 562-735-3226
• Fax: N/A
• Employees: 660
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Oncology Institute: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +63.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -7.42%
• Pretax Margin: -8.00%
• Return on Equity: N/A
• Return on Assets: -24.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.47
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $545.76 million
• Price / Sales: 0.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.16) per share
• Price / Book: -32.41

Miscellaneous

• Outstanding Shares: 98,839,000
• Free Float: 94,490,000
• Market Cap: $512.58 million
• Optionable: Not Optionable
• Beta: 0.39